Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2017

01-12-2017 | Fatty Liver Disease (S Harrison and J George, Section Editors)

What Is the Optimal Dietary Composition for NAFLD?

Authors: Elena S. George, Audrey C. Tierney, Katrina L. Campbell, Graeme A. Macdonald, Ingrid J. Hickman

Published in: Current Hepatology Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

Non-alcoholic fatty liver disease (NAFLD) is a complex condition with multi-organ considerations. Weight reduction effectively reduces steatosis in the short term; however, the effects of dietary composition in the absence of weight loss on hepatic and metabolic measures remain unclear. This review sought to update the evidence for whole of diet approaches and interventions in human studies of NAFLD.

Recent Findings

Assessing dietary composition in NAFLD is complex and requires consideration of food patterns across decades of life. Dietary composition aligned with mostly plant-based, high fibre, unprocessed foods, such as the Mediterranean Diet, can produce hepatic and metabolic benefits in NAFLD irrespective of weight loss. High fructose-sweetened beverages are associated with more severe steatosis, and short-term avoidance has demonstrated rapid improvements in liver health. Regular coffee drinking may have a protective effect against fibrosis in those with established NASH.

Summary

Changing focus from single nutrient to dietary patterns may offer greater translation capability to research findings. Investment in whole food dietary education approaches to engage lifelong health behaviours targeted at culturally appropriate healthy food and lifestyle choices are needed.
Literature
1.
2.
Paris T, George ES, Roberts SK, Tierney AC. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review. Eur J Gastroenterol Hepatol. 2017;
3.
Gil Á, Martínez de Victoria E, Olza J. Indicators for the evaluation of diet quality. Nutricion Hospitalaria. 2015;31(3)
4.
Shivappa N, Steck SE, Hurley TG, Hussey JR, Hébert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr. 2014;17(8):1689–96.PubMedCrossRef
5.
Shivappa N, Hébert JR, Rietzschel ER, De Buyzere ML, Langlois M, Debruyne E, et al. Associations between dietary inflammatory index and inflammatory markers in the Asklepios study. Br J Nutr. 2015;113(4):665–71.PubMedPubMedCentralCrossRef
6.
Cantero I, Abete I, Babio N, Arós F, Corella D, Estruch R, et al. Dietary inflammatory index and liver status in subjects with different adiposity levels within the PREDIMED trial. Clin Nutr. 2017;
7.
Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;2003(348):2599–608.CrossRef
8.
Sotos-Prieto M, Moreno-Franco B, Ordovás JM, León M, Casasnovas JA, Peñalvo JL. Design and development of an instrument to measure overall lifestyle habits for epidemiological research: the Mediterranean Lifestyle (MEDLIFE) index. Public Health Nutr. 2015;18(6):959–67.PubMedCrossRef
9.
10.
Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86(2):285–300.PubMed
11.
12.
Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37(4):909–16.PubMedCrossRef
13.
Solga S, Alkhuraishe AR, Clark JM. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49(10):1578–83.PubMedCrossRef
14.
Valtueña S, Pellegrini N, Ardigò D, Del Rio D, Numeroso F, Scazzina F, et al. Dietary glycemic index and liver steatosis. Am J Clin Nutr. 2006;84(1):136–42.PubMed
15.
Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007;23(1):46–52.PubMedCrossRef
16.
17.
Bian H, Hakkarainen A, Lundbom N, Yki-Järvinen H. Effects of dietary interventions on liver volume in humans. Obesity. 2014;22(4):989–95.PubMedCrossRef
18.
• Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7(11):9127–38. Excellent review updating latest mechanistic evidence for the effects of highly controlled modulation of dietary composition in eucaloric conditions (under research conditions) and potential implications for translation into real world clinical trials. PubMedPubMedCentralCrossRef
19.
• Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56(1):255–66. The most recent systematic review in NAFLD and lifestyle interventions. PubMedCrossRef
20.
Hickman IJ, Byrne NM, Croci I, Chachay VS, Clouston AD, Hills AP et al. A pilot randomised study of the metabolic and histological effects of exercise in non-alcoholic steatohepatitis. Journal of diabetes and Metabolism 2013;4(8).
21.
Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009;136(5):1552–60.PubMedPubMedCentralCrossRef
22.
• Gibson PS, Lang S, Dhawan A, Fitzpatrick E, Blumfield ML, Truby H, et al. Systematic review: nutrition and physical activity in the management of paediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2017;65(2):141–9. The most recent systematic review in paediatric NAFLD and lifestyle interventions. PubMedCrossRef
23.
Yki-Järvinen H. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Current Opinion in Clinical Nutrition & Metabolic Care. 2010;13(6):709–14.CrossRef
24.
Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011; (6).
25.
Schwarz J-M, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. The Journal of Clinical Endocrinology & Metabolism. 2015;100(6):2434–42.CrossRef
26.
27.
28.
29.
Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients. 2014;6(12):5679–703.PubMedPubMedCentralCrossRef
30.
Tappy L, Lê K-A. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clinics and Research in Hepatology and Gastroenterology. 2012;36(6):554–60.PubMedCrossRef
31.
• O'Sullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK, et al. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014;58(5):624–31. Robust dietary methodology in a well-controlled longitudinal study, which identified the confounding issue of body mass index in the relationship between fructose and development of NAFLD. PubMedCrossRef
32.
33.
Schwarz J-M, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology. 2017.
34.
Saab S, Mallam D, Cox GA, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34(4):495–504.PubMedCrossRef
35.
Goh GBB, Chow WC, Wang R, Yuan JM, Koh WP. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology. 2014;60(2):661–9.PubMedPubMedCentralCrossRef
36.
Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res. 2015;165(3):428–36.PubMedCrossRef
37.
Alferink LJ, Fittipaldi J, Kiefte-de Jong JC, Taimr P, Hansen BE, Metselaar HJ et al. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: the Rotterdam study. J Hepatol. 2017.
38.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47(5):711–7.PubMedCrossRef
39.
Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JPA. Cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet. 2014;114(8):1181–94.PubMedCrossRef
40.
Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. Eur J Clin Nutr. 2017;
41.
42.
43.
Aller R, Izaola O, de la Fuente B, de Luis D. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutricion hospitalaria. 2015;32(6):2518–24.PubMed
44.
45.
46.
•• Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138–43. https://​doi.​org/​10.​1016/​j.​jhep.​2013.​02.​012. The first randomised controlled trial demonstrating the efficacy of a MD in biopsy-proven NAFLD patients. PubMedCrossRef
47.
Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23(17):3150.PubMedPubMedCentralCrossRef
48.
49.
Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012;35(7):1429–35.PubMedPubMedCentralCrossRef
50.
Fraser A, Abel R, Lawlor D, Fraser D, Elhayany AA. Modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia. 2008;51(9):1616–22.PubMedCrossRef
51.
52.
Papamiltiadous ES, Roberts SK, Nicoll AJ, Ryan MC, Itsiopoulos C, Salim A, et al. A randomised controlled trial of a Mediterranean dietary intervention for adults with non alcoholic fatty liver disease (MEDINA): study protocol. BMC Gastroenterol. 2016;16(1):1.CrossRef
53.
Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011;14(12A):2274–84.PubMedCrossRef
54.
Visioli F, Galli C. Biological properties of olive oil phytochemicals. Crit Rev Food Sci Nutr. 2002;42(3):209–21.PubMedCrossRef
55.
Sacks F. Dietary fat, the mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000-introduction. 2002.
56.
57.
Slavin JL, Martini MC, Jacobs DR, Marquart L. Plausible mechanisms for the protectiveness of whole grains. Am J Clin Nutr. 1999;70(3):459s–63s.PubMed
58.
Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014;146(6):1564–72.PubMedPubMedCentralCrossRef
59.
Oya J, Nakagami T, Sasaki S, Jimba S, Murakami K, Kasahara T, et al. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. Eur J Clin Nutr. 2010;64(10):1179–85.PubMedCrossRef
60.
61.
62.
63.
64.
Turati F, Trichopoulos D, Polesel J, Bravi F, Rossi M, Talamini R, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol. 2014;60(3):606–11.PubMedCrossRef
65.
Freedman ND, Cross AJ, McGlynn KA, Abnet CC, Park Y, Hollenbeck AR, et al. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst. 2010;102(17):1354–65.PubMedPubMedCentralCrossRef
66.
Keys A, Mienotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol. 1986;124(6):903–15.PubMedCrossRef
67.
Shim P, Choi D, Park Y. Association of Blood Fatty Acid Composition and Dietary Pattern with the risk of non-alcoholic fatty liver disease in patients who underwent cholecystectomy. Ann Nutr Metab. 2017;70(4):303–11.PubMedCrossRef
68.
Yang C-Q, Shu L, Wang S, Wang J-J, Zhou Y, Xuan Y-J, et al. Dietary patterns modulate the risk of non-alcoholic fatty liver disease in Chinese adults. Nutrients. 2015;7(6):4778–91.PubMedPubMedCentralCrossRef
69.
Poulsen SK, Due A, Jordy AB, Kiens B, Stark KD, Stender S, et al. Health effect of the new Nordic diet in adults with increased waist circumference: a 6-mo randomized controlled trial. Am J Clin Nutr. 2014;99(1):35–45.PubMedCrossRef
70.
Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.PubMedPubMedCentralCrossRef
71.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–131.PubMedCrossRef
72.
Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–94.PubMedCrossRef
73.
Boursier J, Diehl AM. Nonalcoholic fatty liver disease and the gut microbiome. Clin Liver Dis. 2016;20(2):263–75.PubMedCrossRef
74.
Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–75.PubMedPubMedCentralCrossRef
75.
76.
Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: a meta-analysis of randomized controlled trials. Hepatology research : the official journal of the Japan Society of Hepatology. 2016;46(12):1226–33. https://​doi.​org/​10.​1111/​hepr.​12671.​ CrossRef
77.
Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol. 2014;13(5):482–8.PubMed
78.
79.
•• Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients. 2016;8(7):397. https://​doi.​org/​10.​3390/​nu8070397. First RCT in NASH demonstrating synbiotics may further enhance metabolic and hepatic benefits achieved with modest weight loss. PubMedCentralCrossRef
80.
St-Onge M-P, Ard J, Baskin ML, Chiuve SE, Johnson HM, Kris-Etherton P, et al. Meal timing and frequency: implications for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation. 2017;135(9):e96–e121.PubMedCrossRef
81.
Hesketh J. Personalised nutrition: how far has nutrigenomics progressed? Eur J Clin Nutr. 2013;67(5):430.PubMedCrossRef
82.
Roche HM. Nutrigenomics—new approaches for human nutrition research. J Sci Food Agric. 2006;86(8):1156–63.CrossRef
83.
Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase -3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883–94.PubMedCrossRef
84.
85.
Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47(9):1940–9.PubMedCrossRef
86.
Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15(5):7352–79.PubMedPubMedCentralCrossRef
87.
Krawczyk M, Grünhage F, Zimmer V, Lammert F. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol. 2011;55(2):299–306.PubMedCrossRef
88.
Shen J-H, Li Y-L, Li D, Wang N-N, Jing L, Huang Y-H. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res. 2015;56(1):167–75.PubMedPubMedCentralCrossRef
89.
Liu Y-L, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5.
90.
Powell EE, Kroon PA. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme a reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. J Clin Investig. 1994;93(5):2168.PubMedPubMedCentralCrossRef
91.
Ziegler-Heitbrock H. Definition of human blood monocytes. J Leukoc Biol. 2000;67(5):603–6.PubMed
92.
de Mello VDF, Kolehmanien M, Schwab U, Pulkkinen L, Uusitupa M. Gene expression of peripheral blood mononuclear cells as a tool in dietary intervention studies: what do we know so far? Mol Nutr Food Res. 2012;56(7):1160–72.PubMedCrossRef
Metadata
Title
What Is the Optimal Dietary Composition for NAFLD?
Authors
Elena S. George
Audrey C. Tierney
Katrina L. Campbell
Graeme A. Macdonald
Ingrid J. Hickman
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0373-7

Other articles of this Issue 4/2017

Current Hepatology Reports 4/2017 Go to the issue

Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences

Fatty Liver Disease (S Harrison and J George, Section Editors)

Role of Exercise in NAFLD/NASH: What is the Right Prescription?

Fatty Liver Disease (S Harrison and J George, Section Editors)

Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making

Fatty Liver Disease (S Harrison and J George, Section Editors)

Non-alcoholic Fatty Liver Disease in Non-obese Patients

Fatty Liver Disease (S Harrison and J George, Section Editors)

Managing HCC in NAFLD

Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Biochemical and Molecular Mechanisms of Liver Damage-Induced by Antidepressant Drugs: an Update Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits